Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Xenetic Biosciences Inc.
DescriptionPolysialylated recombinant Factor VIII
Molecular Target
Mechanism of ActionFactor VIII replacement
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase I
Standard IndicationHemophilia
Indication DetailsTreat hemophilia A
Regulatory Designation
PartnerShire plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today